We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · September 17, 2020

Autologous CMV-Specific T Cells Are a Safe Adjuvant Immunotherapy for Primary GBM

The Journal of Clinical Investigation

 

Additional Info

The Journal of Clinical Investigation
Autologous CMV-Specific T Cells Are a Safe Adjuvant Immunotherapy for Primary Glioblastoma Multiforme
J. Clin. Invest. 2020 Aug 04;[EPub Ahead of Print], C Smith, KE Lineburg, JP Martins, G Ambalathingal, MA Neller, B Morrison, KK Matthews, S Rehan, P Crooks, A Panikkar, L Beagley, L Le Texier, S Srihari, D Walker, R Khanna

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading